IL23A and psoriasis: A meta-analysis of 22 RCTs involving 10,183 psoriasis patients also showed no significant difference in the MACE rate between patients receiving anti–IL-12/IL-23 and placebo, with a Mantel-Haenszel risk difference of 0.012 events/person-year (95% CI: −0.001 to 0.026; p = 0.12) (Ryan et al., 2011), but a higher risk of MACEs in patients receiving IL-12/23 antibodies in comparison with placebo was found after the evaluation of the same trials using another statistical technique named the Peto OR method (Tzellos et al., 2013).